Tozasertib (VX-680, MK-0457)

For research use only. Not for use in humans.

目录号：S1048 中文名称：陶扎色替

Tozasertib (VX-680, MK-0457) Chemical Structure

CAS No. 639089-54-6

Tozasertib (VX-680, MK-0457)是一种pan-Aurora抑制剂，对Aurora A作用最强，无细胞试验中K_iapp为0.6 nM，而对Aurora B/Aurora C的作用较弱，对Aurora A选择性比其他55种激酶高100倍。唯二的例外是 Fms-related tyrosine kinase-3 (FLT-3) 和 BCR-ABL tyrosine kinase，也可被 Tozasertib 抑制，对应的Ki值均为30 nM和30 nM。Tozasertib 可诱导凋亡和自噬。Phase 2。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 1098.34	现货
25mg	RMB 1211.51	现货
100mg	RMB 3017.92	现货
250mg	RMB 3833.09	现货
300mg	RMB 4316.13	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Tozasertib (VX-680, MK-0457)发表文献96篇：

Nature, 2018, 559(7713):211-216.

PubMed: 29973724 ( click the link to review the publication )

Cancer Cell, 2014, 26(3):414-427

PubMed: 25175806 ( click the link to review the publication )

Cell Stem Cell, 2012, 11(2):179-94

PubMed: 22862944 ( click the link to review the publication )

Cell, 2010, 6;142(3):444-55.

PubMed: 20691903 ( click the link to review the publication )

J Cell Biol, 2021, 220(2)e202008029

PubMed: 33355621 ( click the link to review the publication )

PLoS Biol, 2021, 19(1):e3001029

PubMed: 33395410 ( click the link to review the publication )

J Clin Invest, 2020, 139080

PubMed: 33016928 ( click the link to review the publication )

EMBO Rep, 2020, 3;21(4):e49700

PubMed: 32030856 ( click the link to review the publication )

Cancer Res, 2020, 80(18):3841-3854

PubMed: 32690724 ( click the link to review the publication )

Cancers (Basel), 2020, 12(11)E3172

PubMed: 33126775 ( click the link to review the publication )

Cancers (Basel), 2020, 12(9)E2697

PubMed: 32967224 ( click the link to review the publication )

Mol Cancer Ther, 2020, 10.1158/1535-7163.MCT-19-1017

PubMed: 32847978 ( click the link to review the publication )

Mol Cancer Ther, 2020, 19(4):1008-1017

PubMed: 31848297 ( click the link to review the publication )

Sci Adv, 2020, 6(29):eaba1941

PubMed: 32832623 ( click the link to review the publication )

Toxicol Sci, 2020, kfaa103

PubMed: 32617558 ( click the link to review the publication )

Cancer Res, 2019, 79(1):209-219

PubMed: 30389701 ( click the link to review the publication )

Cell Death Differ, 2019, 26(3):548-564

PubMed: 30050055 ( click the link to review the publication )

Cancers (Basel), 2019, 11(10)

PubMed: 31652588 ( click the link to review the publication )

Cell Death Dis, 2019, 10(6):385

PubMed: 31097686 ( click the link to review the publication )

Cell Death Dis, 2019, 10(6):432

PubMed: 31160567 ( click the link to review the publication )

Cell Chem Biol, 2019, 26(3):390-399.e5

PubMed: 30612951 ( click the link to review the publication )

FEBS J, 2019, 286(5):963-974

PubMed: 30600590 ( click the link to review the publication )

Antiviral Res, 2019, 170:104572

PubMed: 31376425 ( click the link to review the publication )

Toxicol Sci, 2019, 10.1093/toxsci/kfz123

PubMed: 31132080 ( click the link to review the publication )
Sci Rep, 2019, 9(1):1897

PubMed: 30760778 ( click the link to review the publication )

Analyst, 2019, 145(1):97-106

PubMed: 31746831 ( click the link to review the publication )

J Pharm Biomed Anal, 2019, doi: 101016/jjpba2019112962

PubMed: 31711864 ( click the link to review the publication )

Environ Mol Mutagen, 2019, 60(6):513-533

PubMed: 30702769 ( click the link to review the publication )

J Pediatr Hematol Oncol, 2019, 41(6):e359-e370

PubMed: 30702467 ( click the link to review the publication )

Int J Mol Sci, 2018, 19(12)

PubMed: 30544932 ( click the link to review the publication )

Cell Signal, 2018, 52:137-146

PubMed: 30223016 ( click the link to review the publication )

SLAS Discov, 2018, 23(2):132-143

PubMed: 28957641 ( click the link to review the publication )

Anticancer Drugs, 2018, 29(10):1004-1010

PubMed: 30080692 ( click the link to review the publication )

Oncotarget, 2018,

PubMed: 29560108 ( click the link to review the publication )

Neuron, 2017, 94(6):1142-1154

PubMed: 28641113 ( click the link to review the publication )

Nat Commun, 2017, 1;8(1):1232

PubMed: 29089541 ( click the link to review the publication )

Cancer Res, 2017, 77(2):494-508

PubMed: 28069801 ( click the link to review the publication )

Oncogene, 2017, 36(44):6177-6189

PubMed: 28869606 ( click the link to review the publication )

Toxicol Sci, 2017, 162(1):146-166

PubMed: 29106658 ( click the link to review the publication )

J Biol Chem, 2017, 292(36):15028-15038

PubMed: 28739871 ( click the link to review the publication )

Cell Signal, 2017, 39:74-83

PubMed: 28780319 ( click the link to review the publication )

Nat Chem Biol, 2016, 10.1038/nchembio.2017

PubMed: 26829474 ( click the link to review the publication )

Nat Commun, 2016, 7:10180

PubMed: 26782714 ( click the link to review the publication )

EMBO J, 2016, 35(8):803-19

PubMed: 26929011 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2016, 113(50):14366-14371

PubMed: 28182563 ( click the link to review the publication )

Elife, 2016, 5:e11402

PubMed: 26878753 ( click the link to review the publication )

Arch Toxicol, 2016, 291(10):4939-54

PubMed: 26404763 ( click the link to review the publication )

J Biol Chem, 2016, 10.1074/jbc.M116.722751

PubMed: 27226586 ( click the link to review the publication )
Exp Cell Res, 2016, 344(2):153-66

PubMed: 27138904 ( click the link to review the publication )

Cell Cycle, 2016, 15(15):2009-18

PubMed: 27249336 ( click the link to review the publication )

Oncol Rep, 2016, 36(2):819-26

PubMed: 27373675 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 473(1):212-8

PubMed: 27003257 ( click the link to review the publication )

Exp Hematol, 2016, 44(3):189-93

PubMed: 26706195 ( click the link to review the publication )

Tumour Biol, 2016, 37(11):14745-14755

PubMed: 27629142 ( click the link to review the publication )

Oncotarget, 2016, 7(18):26580-92

PubMed: 27058891 ( click the link to review the publication )

Nat Cell Biol, 2015, 17(1):31-43

PubMed: 25503564 ( click the link to review the publication )

Nat Commun, 2015, 6:7935

PubMed: 26228240 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(23):5338-48

PubMed: 26152738 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(2):419-28

PubMed: 25522764 ( click the link to review the publication )

Oncol Rep, 2015, 34(2):803-10

PubMed: 26044736 ( click the link to review the publication )

PLoS One, 2015, 10(7):e0134306

PubMed: 26218638 ( click the link to review the publication )

BMC Res Notes, 2015, 8:484

PubMed: 26415506 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(6):1354-64

PubMed: 25873592 ( click the link to review the publication )

J Mol Cell Biol, 2014, 6(3):240-54

PubMed: 24847103 ( click the link to review the publication )

Biochim Biophys Acta, 2014, 1843(5):934-44

PubMed: 24480460 ( click the link to review the publication )

Hum Gene Ther, 2014, 25(7):599-608

PubMed: 24568341 ( click the link to review the publication )

Am J Physiol Lung Cell Mol Physiol, 2014, 307(2):L173-85

PubMed: 24838752 ( click the link to review the publication )

PLoS One, 2014, 9(9):e108758

PubMed: 25268132 ( click the link to review the publication )

PLoS One, 2014, 9(7):e102741

PubMed: 25048812 ( click the link to review the publication )

Oncol Lett, 2014, 7(1):121-124

PubMed: 24348832 ( click the link to review the publication )

Oncotarget, 2014, 5(17):7498-511

PubMed: 25115395 ( click the link to review the publication )

Cancer Res, 2013, 73(22):6722-33

PubMed: 24101154 ( click the link to review the publication )
Cancer Res, 2013, 73(20):6310-22

PubMed: 24067506 ( click the link to review the publication )

Arthritis Rheum, 2013,

PubMed: 23653330 ( click the link to review the publication )

Mol Cancer Res, 2013, 12(3):433-9

PubMed: 24336958 ( click the link to review the publication )

Mol Cancer Res, 2013, 11(11):1326-36

PubMed: 24008673 ( click the link to review the publication )

J Cell Sci, 2013, 126(Pt 5):1235-46

PubMed: 23321637 ( click the link to review the publication )

J Cell Mol Med, 2013, 17(2):265-76

PubMed: 23301855 ( click the link to review the publication )

Vet Comp Oncol, 2013, 10.1111/vco.12018

PubMed: 23410058 ( click the link to review the publication )

Oncotarget, 2013,

PubMed: 23328114 ( click the link to review the publication )

Eur J Cancer, 2012, 48(15):2417-30

PubMed: 22244830 ( click the link to review the publication )

Oncogene, 2012, 31(31):3584-96

PubMed: 22120720 ( click the link to review the publication )

J Med Chem, 2012, 55(17):7392-416

PubMed: 22803810 ( click the link to review the publication )

Brain Pathol, 2012, 23(3):244-53

PubMed: 22971244 ( click the link to review the publication )

J Neurosci, 2012, 32(32):11050-66

PubMed: 22875938 ( click the link to review the publication )

Biochem Pharmacol, 2012, 83(9):1217-28

PubMed: 22306067 ( click the link to review the publication )

Biochem J, 2012, 447(1):93-102

PubMed: 22784093 ( click the link to review the publication )

Exp Cell Res, 2012, 318(4):336-49

PubMed: 22197704 ( click the link to review the publication )

Cytoskeleton, 2012, 69(10):840-53

PubMed: 22887753 ( click the link to review the publication )

J Biomol Screen, 2012, 18(4):388-99

PubMed: 23134735 ( click the link to review the publication )

Pediatr Surg Int, 2012, 28(6):579-89

PubMed: 22526548 ( click the link to review the publication )

Curr Biol, 2011, 21(16):1356-65

PubMed: 21820309 ( click the link to review the publication )

Cancer Res, 2011, 71(23):7207-15

PubMed: 21978935 ( click the link to review the publication )

J Biol Chem, 2011, 286(42):36304-15

PubMed: 21878642 ( click the link to review the publication )

Biochem J, 2011, 440(1):85-93

PubMed: 21774789 ( click the link to review the publication )

Mol Cancer Ther, 2010, 9(5):1318-27

PubMed: 20388735 ( click the link to review the publication )

产品安全说明书

Aurora Kinase抑制剂选择性比较

生物活性

产品描述

靶点

Aurora A ^[1] (Cell-free assay)	Aurora C ^[1] (Cell-free assay)	Aurora B ^[1] (Cell-free assay)	FLT3 ^[4] (Cell-free assay)	Bcr-Abl ^[4] (Cell-free assay)
0.6 nM(Ki app)	4.6 nM(Ki app)	18 nM(Ki app)	30 nM(Ki)	30 nM(Ki)

体外研究

虽然VX-680具有多激酶特性，VX-680却诱导相似的细胞毒性，IC50约为300 nM，在G2/M期，核内复制期，及转染ABL或FLT-3激酶的BaF3细胞凋亡时，显示一个Aurora B 类似的抑制表现型。VX-680抑制CAL-62细胞增殖，这种作用存在时间依赖性。用VX-680处理14天，明显降低群体的数量和大小，处理8305C下降达到70%，处理CAL-62, 8505C,和BHT-101下降达到90%。用VX-680处理不同ATC细胞，抑制细胞增殖，IC50为25到150 nM，这种作用存在时间和剂量依赖性。在软琼脂中，VX-680明显削弱不同细胞系形成群落的能力。caspase-3的活性分析显示VX-680诱导不同细胞凋亡。VX-680处理CAL-62 细胞12小时，形成DNA含量≥4N细胞累积物。微速摄影分析显示VX-680处理的CAL-62细胞离开细胞中期。VX-680可以抑制组蛋白H3的磷酸化作用。^[2] VX-680作用于携带T315I突变的BCR-Abl的病人样本，具有明显抑制活性。^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
BE-13	NWPrW4RST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4LudmlEPTB;MD6wNFM{QCEQvF2=	NGP1SmVUSU6JUlXS
RS4-11	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkO2TWM2OD1yLkCwOFA1KM7:TR?=	MXnTRW5IWkWU
MFH-ino	MoLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{X5bWlEPTB;MD6wNFk6KM7:TR?=	NWSzU2FmW0GQR2LFVi=>
NTERA-S-cl-D1	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEDqPWVKSzVyPUCuNFE1OzRizszN	NUXnVY8zW0GQR2LFVi=>
697	NVHYe3ZrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXPrS5hyUUN3ME2wMlAzPDdzIN88US=>	NYTIPJh[W0GQR2LFVi=>
NALM-6	NWLJV2J6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUDDd49{UUN3ME2wMlAzPTV{IN88US=>	M1;FSXNCVkeURWK=
ES8	NGHCOWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1TvbWlEPTB;MD6wOFYyOyEQvF2=	MlzxV2FPT1KHUh?=
HUTU-80	NXvldXlPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXTJR\|UxRTBwMEWyPVkh\|ryP	M1HKeHNCVkeURWK=
MV-4-11	M2fleGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3yzOGlEPTB;MD6wO\|c5OiEQvF2=	MUnTRW5IWkWU
MONO-MAC-6	NEfzdXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYfJR\|UxRTBwMEe4O\|kh\|ryP	MVfTRW5IWkWU
LC-2-ad	NEn5U5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mly1TWM2OD1yLkC4O\|g6KM7:TR?=	NITvZY9USU6JUlXS
BL-41	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYDJR\|UxRTBwMUC0OFUh\|ryP	MYXTRW5IWkWU
A4-Fuk	Ml3rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGj2TnBKSzVyPUCuNVE2PjNizszN	MXPTRW5IWkWU
SW954	NIn1ZnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH7PSFhKSzVyPUCuNVIzOjlizszN	NEDrbXhUSU6JUlXS
BV-173	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXzSOY1NUUN3ME2wMlEzPjRzIN88US=>	M3HjeHNCVkeURWK=
TE-11	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH2xfWhKSzVyPUCuNVQ6QDJizszN	NVXxdGtvW0GQR2LFVi=>
SK-UT-1	M2\odWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWTJR\|UxRTBwMUW5OlUh\|ryP	M4\VZnNCVkeURWK=
SIG-M5	NH;ZV4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHL4c4lKSzVyPUCuNVY4ODdizszN	MmXrV2FPT1KHUh?=
OCUB-M	NI\ucodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXrJR\|UxRTBwMU[5PFMh\|ryP	NETOd2JUSU6JUlXS
K052	M4D0UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlrHTWM2OD1yLkG5OFgh\|ryP	NIj1OFhUSU6JUlXS
VA-ES-BJ	NX;JdYtlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4W3RWlEPTB;MD6yNFA5PiEQvF2=	MoOwV2FPT1KHUh?=
SW982	NULx[WQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NISxWGlKSzVyPUCuNlE{QCEQvF2=	NInHcXJUSU6JUlXS
LB647-SCLC	NYnQco9sT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnHNTWM2OD1yLkKxOVI{KM7:TR?=	MUjTRW5IWkWU
PSN1	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV3GSVU2UUN3ME2wMlIzODJ4IN88US=>	MnXTV2FPT1KHUh?=
BB30-HNC	M3PHUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYDadYlPUUN3ME2wMlIzPTlzIN88US=>	MmLyV2FPT1KHUh?=
ST486	NWDmXVBVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NILzW3FKSzVyPUCuNlMxQDdizszN	NIPoUIJUSU6JUlXS
MOLT-4	NUnSZoE5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGOxS4ZKSzVyPUCuNlM{OzdizszN	M2DrWnNCVkeURWK=
EW-16	MoO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MofnTWM2OD1yLkKzO\|Y5KM7:TR?=	Ml\VV2FPT1KHUh?=
KS-1	NEHoUYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUfiUoNlUUN3ME2wMlI{Pzh3IN88US=>	MnzVV2FPT1KHUh?=
SR	M3\4eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHfDR3NKSzVyPUCuNlQ2PjRizszN	MYrTRW5IWkWU
KM12	M3G3SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2O0WGlEPTB;MD6yOlM3KM7:TR?=	MYHTRW5IWkWU
EM-2	M{Tn[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mo\wTWM2OD1yLkK2OlQyKM7:TR?=	NWOycoVbW0GQR2LFVi=>
MEG-01	MkfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{Dn[GlEPTB;MD6yO\|g1QSEQvF2=	MWfTRW5IWkWU
NB13	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEjPeYNKSzVyPUCuNlc6QDRizszN	NXrlVo9PW0GQR2LFVi=>
RKO	M2jwU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVXKV3BKUUN3ME2wMlMxQDF\|IN88US=>	NE\DVZVUSU6JUlXS
CESS	MmSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlnlTWM2OD1yLkOxN\|I5KM7:TR?=	NFjJS4NUSU6JUlXS
EoL-1-cell	NHPPfZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX\JR\|UxRTBwM{O0OVkh\|ryP	NXGzbGRSW0GQR2LFVi=>
DOHH-2	NFrPb5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3e1emlEPTB;MD6zN\|c5OSEQvF2=	MWXTRW5IWkWU
A388	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFXG[ohKSzVyPUCuN\|QxQDZizszN	M3nxTXNCVkeURWK=
LAMA-84	NIXqZ5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYO4NoVqUUN3ME2wMlM2OTd6IN88US=>	MmLpV2FPT1KHUh?=
IMR-5	NUm2Um9KT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mm\pTWM2OD1yLkO1OVQh\|ryP	NE\vTJVUSU6JUlXS
KARPAS-422	M{HUfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEm1OmhKSzVyPUCuN\|czPzJizszN	MVrTRW5IWkWU
MRK-nu-1	NW\L[mhQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkjaTWM2OD1yLkO4NVMh\|ryP	MVfTRW5IWkWU
BL-70	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV;JR\|UxRTBwM{i5O\|Qh\|ryP	MVjTRW5IWkWU
LXF-289	NFzhWIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYLNSGt4UUN3ME2wMlQxPDB4IN88US=>	MYPTRW5IWkWU
RL95-2	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHfFZm5KSzVyPUCuOFA2PjdizszN	Mn7HV2FPT1KHUh?=
QIMR-WIL	M4rHeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFLD[3ZKSzVyPUCuOFI3PzZizszN	NXrtO3J[W0GQR2LFVi=>
K-562	NVqyOFZxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NULJU3R3UUN3ME2wMlQ{PDd{IN88US=>	MUfTRW5IWkWU
NCI-H510A	NX;hO\|lRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlrZTWM2OD1yLkSzPFI{KM7:TR?=	MoSxV2FPT1KHUh?=
NCI-H524	MlfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml3ZTWM2OD1yLkWxNVQ4KM7:TR?=	M1zxbHNCVkeURWK=
KE-37	MoTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkDhTWM2OD1yLkWyNVAzKM7:TR?=	MlLwV2FPT1KHUh?=
KP-N-YS	Mm[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVHqdoRzUUN3ME2wMlU1Ozl{IN88US=>	NF3VdIdUSU6JUlXS
LS-411N	NVL3Z2pzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIHWOG9KSzVyPUCuOVc4PTJizszN	MY\TRW5IWkWU
CTV-1	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2XRS2lEPTB;MD61PFc4OyEQvF2=	NVPidW5GW0GQR2LFVi=>
NCI-SNU-16	M{KwNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFvKdIhKSzVyPUCuOlM2PzFizszN	NH\nW3VUSU6JUlXS
HT-144	NUnx[IFkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1XtR2lEPTB;MD62N\|c6QCEQvF2=	NHLkfItUSU6JUlXS
NCI-H187	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4[2N2lEPTB;MD62OFE{KM7:TR?=	MWfTRW5IWkWU
OCI-AML2	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4ew[GlEPTB;MD62OFQxOyEQvF2=	MkDpV2FPT1KHUh?=
CCRF-CEM	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkjrTWM2OD1yLk[1N\|Q3KM7:TR?=	MkjsV2FPT1KHUh?=
ONS-76	NILCNGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVnJR\|UxRTBwNk[0OVgh\|ryP	M2H1UnNCVkeURWK=
IST-SL2	M4THZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUHxO5ZsUUN3ME2wMlcyQTh{IN88US=>	M3O0NnNCVkeURWK=
NB6	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVfJR\|UxRTBwN{eyOVQh\|ryP	MVvTRW5IWkWU
SK-PN-DW	NHvJWlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUL5S3ZUUUN3ME2wMlc6OTRizszN	NVHIWHRXW0GQR2LFVi=>
HCC1599	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkXSTWM2OD1yLkiwPFc1KM7:TR?=	NUDNWHpLW0GQR2LFVi=>
MC116	NFvsTYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUHUS2VIUUN3ME2wMlg2ODFzIN88US=>	MV;TRW5IWkWU
TE-15	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFftXpdKSzVyPUCuPFUxQThizszN	M3vjPHNCVkeURWK=
HOP-62	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmHVTWM2OD1yLki2N\|I6KM7:TR?=	NXTXUZllW0GQR2LFVi=>
TGBC24TKB	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVnJR\|UxRTBwOE[zPFUh\|ryP	MmPQV2FPT1KHUh?=
HCE-4	MmT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NInDXGhKSzVyPUCuPFgxPjNizszN	MmHoV2FPT1KHUh?=
ALL-PO	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2Px[mlEPTB;MD64PFE4PSEQvF2=	MmixV2FPT1KHUh?=
KGN	NVXPPVRmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4\DdWlEPTB;MD64PVk6PSEQvF2=	M3vURXNCVkeURWK=
ML-2	NYHuNJVmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlvaTWM2OD1yLkmwNlU6KM7:TR?=	MX3TRW5IWkWU
ES4	M4HtfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mm\HTWM2OD1yLkmxNVI5KM7:TR?=	M2PFO3NCVkeURWK=
SF126	Mnv1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXi3eWJSUUN3ME2wMlk1QDF7IN88US=>	NEm3c4NUSU6JUlXS
SK-N-DZ	NWX3PWE5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYXLNJZxUUN3ME2wMlk3OTh7IN88US=>	NGTlUJVUSU6JUlXS
HCC1187	NIHmS3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH;jT5FKSzVyPUGuNFA2ODVizszN	NVr4VHp1W0GQR2LFVi=>
DU-4475	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnLVTWM2OD1zLkCxO\|U3KM7:TR?=	NFO5VGtUSU6JUlXS
NKM-1	NVLHdIkyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUTZVWpvUUN3ME2xMlAzPzd3IN88US=>	Mli1V2FPT1KHUh?=
HL-60	NV\1b\|ZsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1jNVmlEPTB;MT6wOlU4PCEQvF2=	MmXkV2FPT1KHUh?=
SBC-1	NH;SN4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlTOTWM2OD1zLkGyOVQzKM7:TR?=	Ml7QV2FPT1KHUh?=
TE-10	Mn3US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX:wT4FPUUN3ME2xMlEzQTR4IN88US=>	NY[5O\|c1W0GQR2LFVi=>
ETK-1	MlnsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXrJR\|UxRTFwMUO2NVMh\|ryP	NVvZ[HFvW0GQR2LFVi=>
HAL-01	NXzDOFhuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGjk[YRKSzVyPUGuNVY4ODlizszN	NFezT45USU6JUlXS
BB65-RCC	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3HWbGlEPTB;MT6xPFAxPSEQvF2=	NWn3UHB[W0GQR2LFVi=>
EW-1	MnfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mo\DTWM2OD1zLkG4OVYzKM7:TR?=	MnziV2FPT1KHUh?=
SK-NEP-1	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWjJR\|UxRTFwMkGxNVEh\|ryP	M2[5b3NCVkeURWK=
SK-LMS-1	Mnf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NED1[lJKSzVyPUGuNlIzOTJizszN	M1y3cXNCVkeURWK=
DEL	M4HPXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYLJR\|UxRTFwMkW2OFMh\|ryP	M{DVcnNCVkeURWK=
GT3TKB	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVLJR\|UxRTFwMkiwOVch\|ryP	NVfncHNyW0GQR2LFVi=>
MOLT-16	M3PCT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVLJR\|UxRTFwM{W0NFUh\|ryP	NF7QdmdUSU6JUlXS
CMK	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1nVT2lEPTB;MT60NlEyPyEQvF2=	NX7iXFJZW0GQR2LFVi=>
NB5	M4nMdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWPLb\|V7UUN3ME2xMlY1OjJ7IN88US=>	NEC0O4xUSU6JUlXS
NCI-H1963	NEjHSW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4fWWGlEPTB;MT63NFU5OyEQvF2=	MYPTRW5IWkWU
KURAMOCHI	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmLCTWM2OD1zLke4PVEyKM7:TR?=	MW\TRW5IWkWU
TE-8	NHPENFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX\JR\|UxRTFwOECzOlgh\|ryP	NEXNcYpUSU6JUlXS
NCI-H1304	NWL1c\|NRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWjBRZZDUUN3ME2xMlg{ODd\|IN88US=>	MmXWV2FPT1KHUh?=
A101D	M2nE[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXPJR\|UxRTFwOEezPVUh\|ryP	M1GzV3NCVkeURWK=
SCLC-21H	NHrBcFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYDJR\|UxRTFwOUewOVch\|ryP	MUDTRW5IWkWU
GB-1	M4j6[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFvqOG5KSzVyPUKuNFE3PDdizszN	M1\LWnNCVkeURWK=
KARPAS-45	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUHJR\|UxRTJwMEK2OVQh\|ryP	NH3ESGhUSU6JUlXS
ATN-1	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEO4OGFKSzVyPUKuNFI5PThizszN	NHvYTJRUSU6JUlXS
NCI-H720	M{CzVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml;6TWM2OD1{LkC2NlQ1KM7:TR?=	NHK2VYdUSU6JUlXS
RPMI-6666	NXPT[IJQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NULzXG9sUUN3ME2yMlE3OjB5IN88US=>	MnfxV2FPT1KHUh?=
NB17	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M13hVWlEPTB;Mj6yPVI4KM7:TR?=	M2jDd3NCVkeURWK=
IST-SL1	MmnIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYmxXmVpUUN3ME2yMlI6PzZ3IN88US=>	M3W3SHNCVkeURWK=
SH-4	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFjYSohKSzVyPUKuN\|I1PjlizszN	NEHNWpBUSU6JUlXS
K5	M322SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVLzXWpnUUN3ME2yMlQxOzF7IN88US=>	NWDTRWx2W0GQR2LFVi=>
OVCAR-4	NWjy[lFrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmToTWM2OD1{LkS2NVMh\|ryP	NX\yPVFoW0GQR2LFVi=>
ACN	NEGxb49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYDCdYM2UUN3ME2yMlUxOjF\|IN88US=>	NGTXdJBUSU6JUlXS
TGW	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUXYO4ZDUUN3ME2yMlY2QDN{IN88US=>	NGH5bVFUSU6JUlXS
NCI-H2107	M1uyUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mlq3TWM2OD1{LkizO\|EyKM7:TR?=	NIHHfIJUSU6JUlXS
NCI-H82	NFrhXnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXvJR\|UxRTJwOEO4N\|gh\|ryP	MlXiV2FPT1KHUh?=
SK-N-FI	Mlr3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV3ldItpUUN3ME2yMlg3QDZ6IN88US=>	Mo\nV2FPT1KHUh?=
LB1047-RCC	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2KzcmlEPTB;Mj64PFEzPiEQvF2=	M2fMO3NCVkeURWK=
LU-134-A	MnK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUnwdIdFUUN3ME2yMlg6OjZizszN	NF76SotUSU6JUlXS
NCI-H209	NI\nVFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVjJR\|UxRTJwOUGyOVMh\|ryP	NV2wPGxsW0GQR2LFVi=>
NOMO-1	M{TJU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWDJR\|UxRTNwMEKyO\|Qh\|ryP	MlnBV2FPT1KHUh?=
RH-1	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGjT[2NKSzVyPUOuNVczQTFizszN	NXHwO5pKW0GQR2LFVi=>
LOUCY	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV63eVVTUUN3ME2zMlE5Pjl\|IN88US=>	MX;TRW5IWkWU
TE-9	MlXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUi2cmZiUUN3ME2zMlI3PzN4IN88US=>	MmTPV2FPT1KHUh?=
PF-382	M{PCTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVfJR\|UxRTNwM{W3O\|gh\|ryP	MkDWV2FPT1KHUh?=
RPMI-8402	MmHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3LwSGlEPTB;Mz61PFYxOyEQvF2=	MlzoV2FPT1KHUh?=
HEL	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHK4eGxKSzVyPUOuOlMzKM7:TR?=	NV23e4hWW0GQR2LFVi=>
NOS-1	M1XGNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUHlV2pGUUN3ME2zMlg1PzV2IN88US=>	M1PaUnNCVkeURWK=
ES1	NVy2cm1WT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYLJR\|UxRTNwOUKyPVMh\|ryP	M2Ww[nNCVkeURWK=
NCI-H2171	Mm\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mom3TWM2OD1\|LkmyOFI{KM7:TR?=	MYnTRW5IWkWU
NCI-H747	NUj0WmdtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1LOUmlEPTB;Mz65OFIzOSEQvF2=	NUHa[4pIW0GQR2LFVi=>
MHH-NB-11	NYGxZ2dPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXe3U4JVUUN3ME2zMlk2OzF{IN88US=>	MoiyV2FPT1KHUh?=
MZ1-PC	Mk\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NY\XfpdNUUN3ME2zMlk6OjRizszN	M3;UbXNCVkeURWK=
MMAC-SF	NI[wTYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MW\JR\|UxRTRwMEK0Olch\|ryP	NGDHUItUSU6JUlXS
NMC-G1	M1v0Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH;q[lBKSzVyPUSuNlI4OjNizszN	Ml;2V2FPT1KHUh?=
SW872	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX\tdGNPUUN3ME20MlM1OzRizszN	NUjU[3hoW0GQR2LFVi=>
TE-12	NYT4fIxIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVH3fWF[UUN3ME20MlU3Ozl2IN88US=>	MXzTRW5IWkWU
LU-139	NHfhTnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYTJR\|UxRTRwNkG4N\|Uh\|ryP	NUfpfFZlW0GQR2LFVi=>
HC-1	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{jrXmlEPTB;ND62PVQ6PCEQvF2=	MULTRW5IWkWU
COR-L279	M2rDOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3\JUGlEPTB;ND63OVg6OSEQvF2=	NGrK[INUSU6JUlXS
SF268	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4X4bGlEPTB;ND63PVkyPiEQvF2=	NXvaNVQ1W0GQR2LFVi=>
MC-CAR	NYmzW\|c5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWnJR\|UxRTVwME[3OVch\|ryP	MXvTRW5IWkWU
TK10	M3Ozc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIHpRXdKSzVyPUWuN\|U1PjlizszN	NEL5fJpUSU6JUlXS
TE-1	M37VXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2fkXmlEPTB;NT60PVAxPCEQvF2=	MYPTRW5IWkWU
NCI-H2126	NVvpUoRLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3ja[GlEPTB;NT62OFU4PCEQvF2=	MVfTRW5IWkWU
Daudi	NGGzSGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1:yUGlEPTB;NT62PVEzKM7:TR?=	M1q4SXNCVkeURWK=
NCI-H1648	M2XwUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUTJR\|UxRTVwOEG0OVQh\|ryP	NFeySWlUSU6JUlXS
OS-RC-2	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnzXTWM2OD13Lkm4OVk4KM7:TR?=	M{HJS3NCVkeURWK=
DJM-1	NI\FW49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGHCdWJKSzVyPU[uN\|Q3PjZizszN	NEewbJRUSU6JUlXS
LS-1034	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUHJR\|UxRTZwN{W2OkDPxE1?	MlG1V2FPT1KHUh?=
NCI-H1581	MoLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4\FR2lEPTB;Nj63PFQxPSEQvF2=	MXvTRW5IWkWU
UACC-257	NUPZSnZGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXTLcWdpUUN3ME23MlA1PTF{IN88US=>	MUPTRW5IWkWU
KM-H2	NHHPXYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4jEN2lEPTB;Nz6xPFQ2PyEQvF2=	M3TqXnNCVkeURWK=
NCI-H1436	MmnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYnJR\|UxRTdwNkm5N\|Ih\|ryP	M{jBRnNCVkeURWK=
IA-LM	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHjjTnBKSzVyPUeuPFU6KM7:TR?=	NXHW[o9kW0GQR2LFVi=>
NCI-H526	NW[ydYo2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4nvS2lEPTB;OD6yOVY{PyEQvF2=	MWjTRW5IWkWU
GCIY	MlzKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmG3TWM2OD16LkO2PVY2KM7:TR?=	MkLjV2FPT1KHUh?=
CP67-MEL	M2fjT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVjJR\|UxRThwNUOyOkDPxE1?	M4jhPXNCVkeURWK=
KALS-1	MojCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mm\ZTWM2OD16LkizPFUyKM7:TR?=	NHX2clFUSU6JUlXS
NCI-H1770	M{DZ[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MU\JR\|UxRThwOUCyOlUh\|ryP	NH7xb4hUSU6JUlXS
8-MG-BA	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWrIVZVQUUN3ME25MlMzQDR2IN88US=>	MVrTRW5IWkWU
KY821	MnXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NI\kfVFKSzVyPUmuO\|c1QDRizszN	MUjTRW5IWkWU
SNB75	M1zLUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1zuNGlEPTB;MUCuNFc3KM7:TR?=	MkniV2FPT1KHUh?=
NCCIT	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MW\JR\|UxRTFzLkC1PFIh\|ryP	NXrQ[4ZMW0GQR2LFVi=>
SJSA-1	M{D1SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mmm4TWM2OD1zMT6yPFkyKM7:TR?=	MlLxV2FPT1KHUh?=
LB373-MEL-D	NUfzcIhrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1;jT2lEPTB;MUGuN\|gzPyEQvF2=	M2q5R3NCVkeURWK=
TALL-1	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1vvfWlEPTB;MUGuOFA2QCEQvF2=	NGfHRnZUSU6JUlXS
NB69	NVf6fmxtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWizXVhkUUN3ME2xNU44PzB3IN88US=>	NFfm[HVUSU6JUlXS
NCI-H1355	NFnEXmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXfJR\|UxRTFzLkm0NlYh\|ryP	M2LSZ3NCVkeURWK=
DMS-153	M4[5PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF3vUndKSzVyPUGyMlA1OjZizszN	NITa[WJUSU6JUlXS
OPM-2	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFjTSmlKSzVyPUGyMlE2QTZizszN	M1PqUXNCVkeURWK=
NB1	NEnaT3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml3OTWM2OD1zMj6yPUDPxE1?	MkTFV2FPT1KHUh?=
A3-KAW	NIXJdm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnzoTWM2OD1zMj6zNlM3KM7:TR?=	MnuwV2FPT1KHUh?=
NCI-H1882	NHjucHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUjJR\|UxRTF{LkSwOlYh\|ryP	NXPneplpW0GQR2LFVi=>
KG-1	M3vqeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoTrTWM2OD1zMj62OVQ2KM7:TR?=	MVLTRW5IWkWU
LC4-1	M{Ha[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV7ZSXFZUUN3ME2xNk44PzB4IN88US=>	Moe0V2FPT1KHUh?=
HCE-T	M4HKTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkPPTWM2OD1zMz6wNFQ6KM7:TR?=	MWPTRW5IWkWU
NEC8	Mn7FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYXER4hmUUN3ME2xN{4yODN6IN88US=>	MnnJV2FPT1KHUh?=
IST-MEL1	M2rDXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVrJR\|UxRTF\|LkW3PFgh\|ryP	NVf5T2I3W0GQR2LFVi=>
EW-3	MniyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUnJR\|UxRTF\|Lke0NFIh\|ryP	MYTTRW5IWkWU
CTB-1	NUXROnhDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{D3bGlEPTB;MUSuNFMzQSEQvF2=	MYTTRW5IWkWU
LS-123	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYrJR\|UxRTF2LkG1PFgh\|ryP	MUPTRW5IWkWU
NCI-H1417	NVXWVIJvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoPBTWM2OD1zND6zNFUzKM7:TR?=	MkX6V2FPT1KHUh?=
MZ7-mel	NGDhPJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV\JR\|UxRTF2LkS0N\|Mh\|ryP	Mk\ZV2FPT1KHUh?=
JiyoyeP-2003	NX\VV4dqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH:xO4JKSzVyPUG1MlY{OjZizszN	M3HUe3NCVkeURWK=
ES6	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGLOXVBKSzVyPUG2MlI{PjFizszN	M1jseHNCVkeURWK=
HH	MlTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4LTdGlEPTB;MUeuNVk3OyEQvF2=	M4fFdHNCVkeURWK=
SF539	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWnJR\|UxRTF5Lkm5NlIh\|ryP	NIq2WXlUSU6JUlXS
Calu-6	NVP4O2h2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWjnU4pJUUN3ME2xPU4zOzlizszN	MkjvV2FPT1KHUh?=
SK-MM-2	NUO4cWdLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFv2co5KSzVyPUG5MlU2PSEQvF2=	Moj1V2FPT1KHUh?=
IST-MES1	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnvBTWM2OD1zOT62OlY{KM7:TR?=	NEP6WmxUSU6JUlXS
GI-ME-N	M1\WOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFPYOYhKSzVyPUG5MlgzOjdizszN	MUDTRW5IWkWU
CAL-148	MnO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmPSTWM2OD1{MD65PVM1KM7:TR?=	MnOwV2FPT1KHUh?=
EVSA-T	M13UR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH7K[2tKSzVyPUKxMlE1QTlizszN	NIn1fo1USU6JUlXS
LP-1	NU[wcWhMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIrnV5JKSzVyPUKxMlM1OzJizszN	NXWwSXoxW0GQR2LFVi=>
BOKU	MmHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIfIfIxKSzVyPUKxMlQ2OzNizszN	M{XLVHNCVkeURWK=
KLE	M3XYZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWHOOotmUUN3ME2yNk4yQTB\|IN88US=>	MWfTRW5IWkWU
LB831-BLC	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mnj5TWM2OD1{NT6xOVI3KM7:TR?=	NWjDO4lYW0GQR2LFVi=>
NCI-H889	MkTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXjJR\|UxRTJ3LkG5N\|Eh\|ryP	NEC5fHpUSU6JUlXS
REH	NUPBOJBPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV\JR\|UxRTJ3LkS2O\|Eh\|ryP	Mnm3V2FPT1KHUh?=
KP-N-RT-BM-1	M2WxXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml;OTWM2OD1{NT60O\|UzKM7:TR?=	NWPs[ZM{W0GQR2LFVi=>
MPP-89	M2K0fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYjJR\|UxRTJ3LkWzNVQh\|ryP	NGDBPGRUSU6JUlXS
no-11	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3WxRWlEPTB;MkWuO\|Q4KM7:TR?=	MkPYV2FPT1KHUh?=
NCI-H748	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWTJR\|UxRTJ3Lke2Nlch\|ryP	MnTPV2FPT1KHUh?=
LB2518-MEL	NETJVm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXraOXV1UUN3ME2yO{4yPzd\|IN88US=>	NFfv[3lUSU6JUlXS
TGBC1TKB	M3XYfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXnJR\|UxRTJ5LkW1PFUh\|ryP	MVXTRW5IWkWU
MHH-PREB-1	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWfJR\|UxRTJ6LkC3N\|Qh\|ryP	NHfCcZhUSU6JUlXS
MZ2-MEL	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{[3VGlEPTB;MkiuOlE1OyEQvF2=	MmrSV2FPT1KHUh?=
U-266	NGX4NoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnKyTWM2OD1{OD62N\|Y3KM7:TR?=	MX3TRW5IWkWU
SNU-C1	MmGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2LRTWlEPTB;MkiuPVQ{KM7:TR?=	NI\k[4dUSU6JUlXS
SW962	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV\JR\|UxRTNyLkK3OFch\|ryP	Mn3UV2FPT1KHUh?=
Raji	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmPoTWM2OD1\|MD61OVkzKM7:TR?=	NUTVR2syW0GQR2LFVi=>
KNS-42	NIjRcm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVjJWmtjUUN3ME2zNE45QTV4IN88US=>	MkG0V2FPT1KHUh?=
LB996-RCC	NVu2VWNHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoHpTWM2OD1\|MT6xO\|AzKM7:TR?=	NEflU2NUSU6JUlXS
CHP-126	MmrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M17GdWlEPTB;M{GuNVk5PCEQvF2=	NWLUT2RWW0GQR2LFVi=>
RXF393	NVrVNI5mT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX;JR\|UxRTN{LkS5O{DPxE1?	MWLTRW5IWkWU
COLO-684	NFHxfHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHG0TWtKSzVyPUOyMlY1OzhizszN	MkjLV2FPT1KHUh?=
A704	NFzFdldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXrVOYJwUUN3ME2zN{42PTN6IN88US=>	NYHTOG9LW0GQR2LFVi=>
A253	MnHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYKwbIRqUUN3ME2zN{42QDV{IN88US=>	NYDXfVlPW0GQR2LFVi=>
KNS-81-FD	MmXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXLtblBjUUN3ME2zOE42PDV4IN88US=>	NV;Ceot3W0GQR2LFVi=>
TE-441-T	NULsN49QT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{PQdGlEPTB;M{SuOlM4OSEQvF2=	M37lO3NCVkeURWK=
HCC2157	NVrBeHIxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1eyXWlEPTB;M{WuOFYyQSEQvF2=	MnrTV2FPT1KHUh?=
ES3	NGfNfGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NW\Lbll{UUN3ME2zOk43PzVizszN	NH\QUIpUSU6JUlXS
NCI-H1155	NULDXpVlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIjYOmlKSzVyPUO3MlgyPSEQvF2=	M4qz[XNCVkeURWK=
SNU-C2B	Mn3GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWn3dnRLUUN3ME2zPE4yPjV2IN88US=>	NX3uRotRW0GQR2LFVi=>
JAR	M1nJWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYXJR\|UxRTN6LkK0OFkh\|ryP	NIXCXYdUSU6JUlXS
GDM-1	M2jLd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUHTNXh6UUN3ME2zPE46OTF4IN88US=>	NV3WfGxtW0GQR2LFVi=>
KU812	MmTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV73fmt2UUN3ME20NU42ODdizszN	NYntS2pPW0GQR2LFVi=>
BC-1	M37JRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1W1Z2lEPTB;NEKuOlc{OSEQvF2=	NHe1ZWpUSU6JUlXS
GI-1	Mo\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUPJR\|UxRTR{LkmxPVIh\|ryP	MYnTRW5IWkWU
NCI-H1694	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{ezfGlEPTB;NESuPVQ4OiEQvF2=	NUfZc4R{W0GQR2LFVi=>
DG-75	NY\4epdxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXnJR\|UxRTR3LkG1O\|ch\|ryP	NYPz[IZYW0GQR2LFVi=>
COR-L88	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHrldG9KSzVyPUS1MlI4PzhizszN	NUH4N2xPW0GQR2LFVi=>
LS-513	M2HuUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn\WTWM2OD12NT65NVU3KM7:TR?=	NXLXTWczW0GQR2LFVi=>
HD-MY-Z	MkLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYP0WG0xUUN3ME20Ok41PjF{IN88US=>	NEjDNJJUSU6JUlXS
L-363	NX20R5hDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NG\DVnJKSzVyPUS2Mlg5OSEQvF2=	MYHTRW5IWkWU
TE-6	NWDxbFBFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{L4c2lEPTB;NEiuOFQ3KM7:TR?=	MWDTRW5IWkWU
NCI-H345	NVfYb4hXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV\VcHpVUUN3ME20PE41PjhizszN	M4LvNnNCVkeURWK=
TE-5	MlPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoPUTWM2OD12OT63NVE5KM7:TR?=	M{O2fnNCVkeURWK=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	DLK / p-MKK7 / MKK7 / p-JNK / JNK ; PubMed: 23431148 Proc Natl Acad Sci U S A Western blot of the DLK pathway members in RGCs (retinal ganglion cells) 4 h after immunopanning in the presence of 0, 0.03, 0.06, 0.125, 0.25, 0.5, 1, or 2 μM tozasertib. p-AURKA / AURKA / Survivin ; PubMed: 28218735 Oncogenesis BGC823 cells were incubated with indicated doses of VX-680 for 24 h before subjected to western blotting with the indicated antibodies. Densitometry was used to quantify the Survivin and GAPDH levels. The relative expression shown (right panel) are means±s.e.m. of the ratios of Survivin to GAPDH. YAP; PubMed: 31160567 Cell Death Dis Western blot analysis of YAP protein level in A549 cells treated with indicated doses of VX-680 for 24 h. p-AKT / p-GSK3β / Cleaved caspase-3 / Cleaved PARP ; PubMed: 21600017 J Transl Med NB4-R2 cells were collected, lysed and subjected to Western blot analysis with cleaved caspase-3, cleaved-PARP, pAkt-1 (Ser473), pGSK-3β (Ser9) specific antibodies. GAPDH was used as a loading control. Data shown is a representative of three independent experiments.	23431148 28218735 31160567 21600017
Immunofluorescence	α-tubulin / Aurora-A ; PubMed: 21600017 J Transl Med The morphology of mitotic spindle was shown by immunofluorescence staining with anti-α-tubulin antibody and anti-Aur-A antibodies. Microtubules were stained as green, Aur-A protein as red, and nucleus as blue.	21600017
Growth inhibition assay	Cell viability; PubMed: 21600017 J Transl Med VX-680 significantly suppresses the proliferation in a number of leukemic cell types. OCI-AML3, NB4, HL-60 and ML-1 cells were incubated with increasing doses of VX-680 (1, 2, 5 and 10 nM) for 24 hr. Cell viability was measured by MTT assay. Data summarized three independent experiments, p < 0.05, *p < 0.01, compared to control.	21600017

体内研究

VX-680作用于人类AML(HL-60)移植瘤模型明显降低肿瘤尺寸。VX-680按75 mg/kg剂量给药实验鼠,每天腹腔注射两次，持续13天,与对照组相比，平均肿瘤体积下降达98%。肿瘤体积比实验之前初始体积小很多。按12.5 mg/kg剂量每天给药两次，肿瘤生长也明显降低，这种作用存在剂量依赖性。VX-680耐受性很好，只有在使用高剂量时可以观察到实验动物体重稍微降低。通过比较cisplatin,按5.4 mg/kg剂量给药，每四天腹腔注射一次，一共进行三次，抑制肿瘤生长只达9%。VX-680作用于胰脏和结肠移植瘤，也引起肿瘤衰退。VX-680静脉注射给药携带HCT116肿瘤的实验鼠，显示很强的抗癌活性。使用高剂量VX-680(每小时2 mg/kg)处理，明显提高效果，比实验钱的初始肿瘤平均尺寸下降56%。^[1]

激酶实验： ^[3]	- 合并激酶抑制实验: 丙酮酸激酶/乳酸脱氢酶催化NADH的氧化，伴随着ATP的消耗，观察340 nm 处吸光值的降低。反应包括100 mM Tris (pH 为 8), 10 mM MgCl₂, 2.2 mM ATP, 1 mM磷酸烯醇丙酮酸, 0.6 mg/ml NADH, 75 ml丙酮酸激酶, 105 ml 乳酸脱氢酶,和0.5 mM 基底肽(序列为EAIYAAPFAKKK)。加入足够的激酶开始反应，反应的激酶浓度达到30 nM，用微量滴定板分光光度计在30^oC进行30分钟，观察吸收率的降低。通过加入3.75 μl 溶于100% DMSO的VX-680 或单独DMSO，获得抑制常数。按如下公式计算K_i值，K_i = IC50/(1+[S]/K_d),[S]=[ATP]=2.2 mM, K_d=70 μM。假定作用于野生型和H396P Abl 激酶域的K_d(ATP)为70 μM，计算以上各值。
细胞实验： ^[2]	- 合并 Cell lines: CAL-62细胞 Concentrations: 5-500 nM Incubation Time: 4天 Method: 对照组CAL-62细胞培养在二甲亚砜和DMSO中，实验组加入500 nM VX-680，处理1到5天。加入不同浓度(5到500 nM) Aurora抑制剂处理不同ATC细胞4天，用来测定VX-680作用于细胞增殖的剂量依赖性。细胞在温育结束前加30 mM BrdU标记，脉冲2小时。通过比色免疫分析使用细胞增殖ELISA试剂盒分析BrdU的合并率。通过比较VX-680处理的细胞和对照组细胞得到结果， (Only for Reference)
动物实验： ^[1]	- 合并 Animal Models: 右侧腋窝处皮下注射107 HL-60白血病细胞的雌性无胸腺NCr-nu鼠 Dosages: 50 mg/kg, 75 mg/kg Administration: 腹腔注射 (Only for Reference)

参考文献

[4] Cheetham GM, et al. Cancer Lett. 2007, 251(2), 323-329.

- 合并

溶解度 (25°C)

体外	DMSO	93 mg/mL (200.17 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 5% DMSO+30% PEG 300+2% Tween 80+ddH2O	15mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Tozasertib (VX-680, MK-0457) SDF

分子量	464.59
化学式	C₂₃H₂₈N₈OS
CAS号	639089-54-6
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	N/A

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

Aurora Kinase Signaling Pathway Map

Aurora Kinase Inhibitors with Unique Features

泛Aurora Kinase抑制剂

Danusertib (PHA-739358) : Pan-Aurora kinase inhibitor, Aurora A/B/C, IC50=13 nM/79 nM/61 nM.
泛Aurora Kinase抑制剂

SNS-314 Mesylate : Pan-Aurora kinase inhibitor, Aurora A/B/C, IC50=9 nM/31 nM/3 nM.
活性最高的Aurora Kinase抑制剂

MK-5108 (VX-689) : Aurora A, IC50=0.064 nM.
用于临床的Aurora Kinase抑制剂

Alisertib (MLN8237) : Phase III for Relapsed/Refractory Peripheral T-Cell Lymphoma.
经典的Aurora Kinase抑制剂

Hesperadin : Potently inhibits Aurora B with IC50 of 250 nM.

研究领域

产品类型

定制您的化合物库

Tozasertib (VX-680, MK-0457)

客户使用Selleck生产的Tozasertib (VX-680, MK-0457)发表文献96篇：

产品安全说明书

Aurora Kinase抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Tozasertib (VX-680, MK-0457) SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

技术支持

Aurora Kinase Signaling Pathway Map

Aurora Kinase Inhibitors with Unique Features

相关Aurora Kinase产品